Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways
Namodenoson, an A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) agonist, is currently being used in a phase III trial in advanced liver cancer. We examined the anti-growth effect of namodenoson on pancreatic carcinoma cells and investigated the molecular mechanism involved. BxPC-3 pancreatic carc...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI AG
2023-10-01
|
| Sarja: | Biomolecules |
| Aiheet: | |
| Linkit: | https://www.mdpi.com/2218-273X/13/11/1584 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|